Turner Syndrome: Clinical Trials

14 trials for Turner Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 2 active not recruiting, 2 recruiting. 14 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 314Completed 10, Active not recruiting 2, Recruiting 2

Follow Turner Syndrome: new trials by email Literature Review of Turner Syndrome trials Research Report on Turner Syndrome

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
Inpegsomatropin-Injection, Givopegsomatropin Solution Injection - Turner Syndrome
Phase 3RecruitingXiamen Amoytop Biotech Co., Ltd.842026-07-052026-07-22
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector - Turner Syndrome, Short Stature Homeobox Gene Mutation
Phase 3RecruitingAscendis Pharma A/S1862025-12-122026-11-05
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
Somapacitan - SGA, Turner Syndrome
Phase 3Active not recruitingNovo Nordisk A/S472023-02-012026-08-13
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
Somapacitan, Norditropin® - SGA, Turner Syndrome, Noonan Syndrome, ISS
Phase 3Active not recruitingNovo Nordisk A/S4122022-08-102026-06-12
A Clinical Study to Assess the Efficacy and Safety of DA-3002
DA-3002, Genotropin® - Turner's Syndrome
Phase 3CompletedDong-A ST Co., Ltd.582013-02-012018-07-26
An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG
ZOMACTON - Turner's Syndrome
Phase 3CompletedFerring Pharmaceuticals272005-10-012011-05-20
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
Somatropin (rDNA origin) - Turner Syndrome, Renal Insufficiency, Chronic
Phase 3CompletedIpsen2512004-06-012019-12-09
Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
17 beta estradiol - Turner Syndrome, Hypogonadism
Phase 3CompletedNemours Children's Clinic162001-01-012017-11-30
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children
Phase 3CompletedNovo Nordisk A/S1682000-10-232017-02-27
The Effect of Growth Hormone in Very Young Girls With Turner Syndrome
Somatropin - Turner Syndrome
Phase 3CompletedEli Lilly and Company1001999-08-012006-12-04
Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome
17-beta estradiol - Genetic Disorder, Turner Syndrome
Phase 3CompletedNovo Nordisk A/S501998-07-232017-02-28
The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome
estrogen, androgen, placebo - Turner Syndrome
Phase 3CompletedThomas Jefferson University2001992-11-012012-06-05
Somatropin Treatment to Final Height in Turner Syndrome
Somatropin, Ethinyl estradiol, Medroxyprogesterone acetate - Turner Syndrome
Phase 3CompletedEli Lilly and Company1541989-02-012010-01-27
Use of Somatropin in Turner Syndrome
somatropin - Genetic Disorder, Turner Syndrome
Phase 3CompletedNovo Nordisk A/S571987-09-142017-02-28

Narrower conditions

Dwarfism (4)  ·  Genetic Diseases, Inborn (3)  ·  Noonan Syndrome (3)  ·  Failure to Thrive (2)  ·  Chromosome Disorders (1)  ·  Endocrine System Diseases (1)  ·  Hypogonadism (1)  ·  Pituitary Diseases (1)  ·  Primary Ovarian Insufficiency (1)  ·  Renal Insufficiency, Chronic (1)  ·  Sex Chromosome Disorders (1)  ·  Sex Chromosome Disorders of Sex Development (1)  ·  Syndrome (1)

Broader conditions

Cardiovascular Abnormalities (14)  ·  Cardiovascular Diseases (14)  ·  Congenital Abnormalities (14)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14)  ·  Disorders of Sex Development (14)  ·  Female Urogenital Diseases (14)  ·  Female Urogenital Diseases and Pregnancy Complications (14)  ·  Gonadal Disorders (14)  ·  Gonadal Dysgenesis (14)  ·  Heart Defects, Congenital (14)  ·  Heart Diseases (14)  ·  Male Urogenital Diseases (14)  ·  Urogenital Abnormalities (14)  ·  Urogenital Diseases (14)  ·  Chromosome Disorders (13)

Interventions

Human Growth Hormone (7)  ·  Estradiol (2)  ·  Growth Hormone (2)  ·  somapacitan (2)  ·  Androgens (1)  ·  Estrogens (1)  ·  Ethinyl Estradiol (1)  ·  Medroxyprogesterone Acetate (1)  ·  lonapegsomatropin (1)

Sponsors

Novo Nordisk A/S (5)  ·  Eli Lilly and Company (2)  ·  Ascendis Pharma A/S (1)  ·  Dong-A ST Co., Ltd. (1)  ·  Ferring Pharmaceuticals (1)  ·  Ipsen (1)  ·  Nemours Children's Clinic (1)  ·  Thomas Jefferson University (1)  ·  Xiamen Amoytop Biotech Co., Ltd. (1)

Countries

United States (6)  ·  Spain (5)  ·  France (4)  ·  South Korea (4)  ·  Germany (3)  ·  Italy (3)  ·  Netherlands (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Canada (2)  ·  China (2)  ·  Czechia (2)  ·  Finland (2)  ·  Greece (2)  ·  Israel (2)

Top investigators

Byung Kyu Suh, M.D., Ph.D. (1)  ·  Chang Jong Kim, M.D., Ph.D. (1)  ·  Cheol Woo Ko, M.D., Ph.D. (1)  ·  Choong Ho Shin, M.D., Ph.D. (1)  ·  Dong Kyu Jin, M.D.,Ph.D. (1)  ·  Han Wook Yoo, M.D., Ph.D. (1)  ·  Heon Suk Han, M.D., Ph.D. (1)  ·  Ho Seong Kim, M.D., Ph.D. (1)

Results publications

PMID 15784709, PMID 16757526, PMID 20733274, PMID 21619701, PMID 34893062, PMID 41712606, PMID 41774755

NIH funding

2004 (1)